All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
On August 15, 2023, the U.S. Food and Drug Administration (FDA) accepted a supplemental new drug application and granted priority review to oral ivosidenib tablets, a potent and targeted inhibitor of mutant IDH1, for the treatment of patients with IDH1-mutated relapsed/refractory (R/R) myelodysplastic syndromes (MDS).1
Oral ivosidenib has previously been approved by the FDA as a monotherapy and in combination with azacitidine for the treatment of patients aged ≥75 years or who are ineligible for intensive induction chemotherapy with newly diagnosed (ND) IDH1-mutated acute myeloid leukemia (AML).1 Oral ivosidenib was also recently approved by the European Commission for a subset of the same patient population: those with IDH1R132 mutations.1
This supplemental new drug application is based on results from a multicenter, open-label, phase I study (NCT02074839), previously covered by the MDS Hub, that found oral ivosidenib produced durable remissions and an acceptable safety profile in patients with R/R IDH1-mutated MDS.1
Updates from #ASCO23 and EHA on the efficacy and safety of ivosidenib, including molecular characterization and long-term follow-up in patients with mutant IDH1 AML and R/R MDS
At the ASCO and EHA congresses, updates were presented on the efficacy...
“How I treat” case studies incorporating updated classification systems
Here, we summarize key points from a “How I treat” article by Chaer et al., published in Blood, discussing the treatment of patients with AML under the new ELN, ICC, and WHO...
Subscribe to get the best content related to MDS delivered to your inbox